Positive effects of intravenous zoledronic acid on bone remodeling and structure: Are different effects on osteoblast activity to other oral Bisphosphonates responsible?

被引：11

作者：

Ebeling, Peter R. ^{[2
]}

Burr, David B. ^{[1
]}

机构：

[1] Indiana Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA

[2] Univ Melbourne, Western Hosp, Dept Med RMH WH, Footscray, Vic 3011, Australia

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2008年 / 23卷 / 01期

关键词：

D O I：

10.1359/JBMR.071101

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：2 / 5

页数：4

共 28 条

[1]

Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate [J].

Allen, Matthew R. ;

Iwata, Ken ;

Phipps, Roger ;

Burr, David B. .

BONE, 2006, 39 (04) :872-879

[2]

BIKLE DD, 1994, J BONE MINER RES, V9, P1777

[3]

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[4]

Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].

Black, Dennis M. ;

Schwartz, Ann V. ;

Ensrud, Kristine E. ;

Cauley, Jane A. ;

Levis, Silvina ;

Quandt, Sara A. ;

Satterfield, Suzanne ;

Wallace, Robert B. ;

Bauer, Douglas C. ;

Palermo, Lisa ;

Wehren, Lois E. ;

Lombardi, Antonio ;

Santora, Arthur C. ;

Cummings, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938

[5]

Boivin G., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P538

[6]

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women [J].

Boivin, GY ;

Chavassieux, PM ;

Santora, AC ;

Yates, J ;

Meunier, PJ .

BONE, 2000, 27 (05) :687-694

[7]

Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].

Bone, HG ;

Hosking, D ;

Devogelaer, J ;

Tucci, JR ;

Emkey, RD ;

Tonino, RP ;

Rodriguez-Portales, JA ;

Downs, RW ;

Gupta, J ;

Santora, AC ;

Liberman, UA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199

[8]

Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography [J].

Borah, B ;

Dufresne, TE ;

Ritman, EL ;

Jorgensen, SM ;

Liu, S ;

Chmielewski, PA ;

Phipps, RJ ;

Zhou, XJ ;

Sibonga, JD ;

Turner, RT .

BONE, 2006, 39 (02) :345-352

[9]

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography [J].

Borah, B ;

Dufresne, TE ;

Chmielewski, PA ;

Johnson, TD ;

Chines, A ;

Manhart, MD .

BONE, 2004, 34 (04) :736-746

[10]

BOYCE RW, 1995, J BONE MINER RES, V10, P211

← 1 2 3 →